Table 2.
Cohort Demographics, Medical and Social Histories, and Lung Function Test Results
| Variable | All Patients (N = 315) | ICI-P (n = 30) | No ICI-P (n = 285) |
|---|---|---|---|
| Age, yr | 66 (58-73) | 62 (58.3-70.5) | 66 (58-73) |
| Male sex | 158 (50.2) | 19 (63.3) | 139 (48.8) |
| Race | |||
| White | 249 (79.0) | 23 (76.7) | 226 (79.3) |
| Black | 58 (18.4) | 7 (23.3) | 51 (17.9) |
| Asian | 1 (0.3) | 0 (0.0) | 1 (0.4) |
| Other | 7 (2.2) | 0 (0.0) | 7 (2.5) |
| Smoking history | |||
| Ever | 287 (91.1) | 29 (96.7) | 258 (90.5) |
| Current | 55 (19.2) | 5 (17.2) | 50 (19.4) |
| Never | 28 (8.9) | 1 (3.3) | 27 (9.5) |
| Pack years | 36.5 (25-50) | 30 (25-47) | 40 (25-50) |
| Pulmonary disease history | |||
| Asthma | 21 (6.7) | 2 (6.7) | 19 (6.7) |
| COPD | 127 (40.3) | 18 (60.0) | 109 (38.2) |
| ILD | 5 (1.6) | 3 (10.0) | 2 (0.7) |
| Othera | 7 (2.2) | 3 (10.0) | 4 (1.4) |
| Autoimmune or CTD history | 10 (3.2) | 1 (3.3) | 9 (3.2) |
| History of chronic infection | |||
| HIV | 3 (1.0) | 2 (6.7) | 1 (0.4) |
| Hepatitis C | 4 (1.3) | 1 (3.3) | 3 (1.1) |
| Baseline spirometry | |||
| Normal results | 11 (3.5) | 0 (0.0) | 11 (3.9) |
| Obstructionb | 47 (14.9) | 6 (20.0) | 41 (14.4) |
| Restrictionc | 18 (5.7) | 3 (10.0) | 15 (5.3) |
| No spirometry performed | 239 (75.9) | 21 (70.0) | 218 (76.5) |
| Dlco % predictedd | 59.9 ± 17.1 | 54.9 ± 15.0 | 60.6 ± 17.4 |
All data are presented as No. (%), median (interquartile range), or mean ± SD. CTD = connective tissue disease, Dlco = diffusion capacity for carbon monoxide; ICI-P = immune checkpoint inhibitor-related pneumonitis; ILD = interstitial lung disease.
a
Sarcoidosis, pulmonary hypertension, and fungal or mycobacterial pulmonary infection.
b
FEV1 to FVC ratio less than lower limit of normal.
c
Normal FEV1 to FVC ratio and FVC less than lower limit of normal.
d
Obtained in 69 of 315 patients (21.9%).